| Diffuse Large B-Cell Lymphoma |
1 |
1 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.9 |
| Skin Cancer |
0 |
0.74 |
| Genomic Medicine |
0 |
0.71 |
| Peripheral T-cell Lymphoma |
0 |
0.55 |
| Breast Cancer |
0 |
0.46 |
| B-Cell Lymphoma |
0 |
0.99 |
| Chemotherapy |
0 |
0.41 |
| Lymphoma |
0 |
0.41 |
| Oncogene |
0 |
0.41 |
| HER2-Negative Breast Cancer |
0 |
0.35 |
| Adverse Effects |
0 |
0.2 |
| Breast |
0 |
0.2 |
| Cancer |
0 |
0.2 |
| Epigenetics |
0 |
0.2 |
| Hematology |
0 |
0.2 |
| Histone Deacetylase Inhibitor |
0 |
0.2 |
| Hypokalemia |
0 |
0.2 |
| Illinois |
0 |
0.2 |
| Patient Safety |
0 |
0.2 |
| Pneumonia |
0 |
0.2 |